Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Conditions
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
- PROCEDURE: Biopsy
- PROCEDURE: Biospecimen Collection
- DRUG: Carboplatin
- PROCEDURE: Computed Tomography
- DRUG: Etoposide
- DRUG: Ifosfamide
- DRUG: Lenalidomide
- PROCEDURE: Positron Emission Tomography
- BIOLOGICAL: Tafasitamab
Sponsor
David Bond, MD